# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

#### <u>AMENDMENTS</u>

#### Please amend the claims as follows:

Claims 1 - 71 (cancelled)

72. (Currently amended) A method of modulating cells that express 19P1E8, the method comprising:

administering to the cells <u>that express 19P1E8</u> an altering composition, whereby the composition alters the status of 19P1E8 or alters the status of a molecule that is modulated by 19P1E8,

whereby cells that express 19P1E8 are modulated.

73. (Currently amended) A method in accordance with claim 72 wherein said modulating results incomprises inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells <u>an altering</u> composition comprising an antibody or fragment thereof both of which specifically bind to [[an]] <u>a</u> 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

74. (Currently amended) A method in accordance with claim 72 wherein said modulating results in comprises inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells <u>an altering</u> <u>composition comprising</u> a vector that encodes an antibody or fragment thereof both of which immunospecifically bind to [[an]] <u>a</u> 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

75. (Previously added) A method of claim 74 further comprising a step of: releasing antibody from cells that express the antibody.

76. (Previously added) A method of claim 73: wherein said antibody is a single chain monoclonal antibody.

77. (Currently amended) A method in accordance with claim 72 wherein said modulating results in comprises inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells <u>an altering</u>
<a href="mailto:composition">composition comprising</a> a ribozyme that cleaves RNA essential for expression of 19P1E8,
whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival
of cancer cells that express 19P1E8 being inhibited.

78. (Currently amended) A method in accordance with claim 72 wherein said modulating results in comprises inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells <u>an altering</u> composition comprising an antisense polynucleotide to an RNA essential for expression of 19P1E8,

whereby cells that express 19P1E8 are modulated bi virtue of the by their growth or survival-of cancer cells that express 19P1E8 being inhibited.

79. (Currently amended) A method in accordance with claim 72 wherein said modulating results incomprises inhibiting growth or survival of cancer-cells that express 19P1E8: wherein the administering step comprises administering to said cells an altering composition comprising a substance that inhibits the secretion of 19P1E8 from said cells, whereby said cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

80. (Currently amended) A method of treating a subject comprising which method comprises cells that express 19P1E8 by modulating said cells, the method comprising:

administering to the cells, *in vivo* or *ex vivo*, an altering composition, whereby the composition alters the status of 19P1E8 or alters the status of a molecule that is modulated by 19P1E8,

whereby cells that express 19P1E8 are modulated and the subject receives some treatment effect.

81. (Currently amended) A method in accordance with claim 80 wherein said treating is effected bycomprises inhibiting growth or survival of eancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject <u>an altering</u> composition comprising an antibody or fragment thereof both of which specifically bind to [[an]] <u>a</u> 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

82. (Currently amended) A method in accordance with claim 80 wherein said treating is effected by comprises inhibiting growth or survival of eancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject <u>an altering</u> <u>composition comprising</u> a vector that encodes an antibody or fragment thereof both of which immunospecifically binds to an 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

- 83. (Previously added) A method of claim 82 further comprising a step of: releasing antibody from cells that express the antibody.
- 84. (Previously added) The method of claim 82, wherein said antibody is a single chain monoclonal antibody.

85. (Currently amended) A method in accordance with claim 80 wherein said treating is effected by comprises inhibiting growth or survival of eancer-cells that express 19P1E8:

wherein the administering step comprises administering to said subject <u>an altering</u> composition comprising a ribozyme that cleaves RNA essential for expression of 19P1E8,

whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

86. (Currently amended) A method in accordance with claim 80 for inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject <u>an altering</u> composition comprising an antisense polynucleotide,

whereby cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

87. (Currently amended) A method in accordance with claim 80 for inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject an altering composition comprising a substance that inhibits the secretion of 19P1E8 from said cells,

whereby said cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

88. (Currently amended) A method in accordance with claim 80 wherein said treating is effected by comprises inhibiting growth or survival of eancer-cells that express 19P1E8:

wherein the administering step comprises administering to said subject <u>an altering</u> composition comprising [[an]] a 19P1E8 protein,

whereby an immune response [[if]] is generated, and

whereby said cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

89. (Currently amended) A method in accordance with claim 80 wherein said treating is effected by comprises inhibiting growth or survival of eancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells <u>an altering</u> composition comprising a vector that comprises a polynucleotide comprising [[an]] <u>a</u> 19P1E8 protein coding sequence, <u>whereby</u>:

### a 19P1E8 protein is encoded;

whereby an immune response [[if]] is generated to said 19P1E8 protein, and whereby said cells that express 19P1E8 are modulated by virtue of the their growth or survival of cancer cells that express 19P1E8 being inhibited.

- 90. (New) A method in accordance with claim 72 wherein said administering is to cells *ex vivo*.
- 91. (New) A method in accordance with claim 72 wherein said administering is to cells *in vivo*.